Latest On Taro Pharmaceutical Industries Ltd (TARO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-27 06:58 EST | News | Taro Pharma weighing offer from Sun Pharma to acquire company at $38 share | N/A |  |
| 2023-05-26 02:24 EST | News | Taro Pharmaceutical misses top and bottom line consensus for Q4 | N/A | |
| 2023-05-24 07:55 EST | News | Taro Pharmaceutical misses top and bottom line consensus for Q1 | N/A | |
| 2023-02-24 09:00 EST | News | Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold | N/A | |
| 2023-01-24 19:49 EST | News | Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M | N/A | |
| 2023-01-05 00:19 EST | News | Jazz Pharma files patent infringement suit against Teva, Taro over generic Epidiolex | N/A | |
| 2022-10-28 06:19 EST | News | Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M | N/A | |
| 2022-10-26 23:11 EST | News | Taro Pharmaceutical Q2 2023 Earnings Preview | N/A | |
| 2022-08-16 14:27 EST | News | Intellipharmaceutics inks license deal with Taro for depression tablets desvenlafaxine | N/A | |
| 2022-08-15 22:08 EST | News | Taro Pharmaceutical hits 52-week low; down 28% YTD | N/A | |
| 2022-08-15 22:08 EST | News | Hot Stocks: REV surges 30%; TRQ plunges; HRB sets 52-week high; TARO hits 52-week low | N/A | |
| 2022-08-12 08:21 EST | News | Taro recalls certain lots of bone disorder drug in Canada on particulate matter concerns | N/A | |
| 2022-07-28 00:27 EST | News | Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M | N/A | |
| 2022-07-13 21:35 EST | News | Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card | N/A | |
| 2022-05-27 09:58 EST | News | Taro Pharmaceutical GAAP EPS of $0.73, revenue of $143.26M | N/A | |
| 2022-05-26 00:57 EST | News | Taro Pharmaceutical Q1 2022 Earnings Preview | N/A | |
| 2022-02-22 11:04 EST | News | Taro Pharmaceutical to acquire Alchemee from Galderma | N/A | |
| 2022-01-27 21:01 EST | News | Taro Pharmaceutical GAAP EPS of $0.70 misses by $0.21, revenue of $138.98M misses by $3.24M | N/A | |
| 2022-01-27 03:51 EST | News | Taro Pharmaceutical Q3 2022 Earnings Preview | N/A | |
| 2021-12-02 05:33 EST | News | Taro Pharmaceutical names new finance chief | N/A | |
| 2021-10-29 05:58 EST | News | Taro Pharmaceutical EPS misses by $0.36, misses on revenue | N/A | |
| 2021-10-04 13:43 EST | News | Taro Pharmaceutical to pay $213M over price fixing allegtions | N/A | |
| 2021-07-28 10:37 EST | News | Taro Pharmaceutical EPS beats by $0.25, beats on revenue | N/A | |
| 2021-07-22 02:18 EST | News | Taro Pharma's CFO Daphne Huang resigns | N/A | |
| 2021-02-02 12:57 EST | Analyst Rating | The Analyst Target Price has increased from $80 to $81. | Buy | |
| 2021-01-30 08:39 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-28 08:33 EST | Earnings Estimate | An EPS average of $0.82 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-01-27 21:33 EST | News | Taro Pharmaceutical EPS misses by $0.15, misses on revenue | N/A | |
| 2020-11-26 21:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-24 09:12 EST | Analyst Rating | The Analyst Target Price has decreased from $82 to $80. | Neutral | |
| 2020-11-08 01:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 08:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 02:23 EST | News | Taro Pharmaceutical EPS beats by $0.41, beats on revenue | N/A | |
| 2020-11-01 02:14 EST | News | Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2020-09-29 10:32 EST | News | Taro Pharmaceutical launches generic Deferiprone in U.S. | N/A | |
| 2020-09-26 14:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 10:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-07 05:48 EST | Earnings Estimate | An EPS average of $4.67 is estimated for the 2022 year. | Buy | |
| 2020-08-06 14:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 09:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 10:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 05:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 05:58 EST | Earnings Estimate | An EPS average of $1.31 is estimated for the quarter ending on December 31, 2020. | Buy | |
| 2020-07-30 05:12 EST | News | Taro Pharmaceutical EPS of -$11.37 | N/A | |
| 2020-07-29 22:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 06:04 EST | Analyst Rating | The Analyst Target Price has decreased from $96 to $82. | Neutral | |
| 2020-07-27 13:54 EST | Financials | Company financials have been released. | Neutral | |
About Taro Pharmaceutical Industries Ltd (TARO):
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
General
- Name Taro Pharmaceutical Industries Ltd
- Symbol TARO
- Type Common Stock
- Exchange NYSE
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 1,464
- Last Split Factor2:1
- Last Split Date2001-07-27
- Fiscal Year EndMarch
- IPO Date1993-04-01
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.taro.com
View More
Valuation
- Trailing PE 10.6
- Forward PE 20.08
- Price/Sales (Trailing 12 Mt.) 5.2
- Price/Book (Most Recent Quarter) 1.7
- Enterprise Value Revenue 3.33
- Enterprise Value EBITDA 4.58
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$8.41
- Next Year EPS Estimate $3.87
- Next Quarter EPS Estimate $0.99
- Profit Margin -53%
- Operating Margin 29%
- Return on Assets 4%
- Return on Equity -17%
- Revenue 575.56 million
- Earnings Per Share $6.35
- Revenue Per Share $15.04
- Gross Profit 399.73 million
- Quarterly Earnings Growth -5.1%
View More
Highlights
- Market Capitalization 2.99 billion
- EBITDA 187.02 million
- Analyst Target Price $81
- Book Value Per Share $46.00
View More
Share Statistics
- Shares Outstanding 38.26 million
- Shares Float 8.76 million
- % Held by Insiders 7710%
- % Held by Institutions 13.26%
- Shares Short 128331
- Shares Short Prior Month 122437
- Short Ratio 4.23
- Short % of Float 1%
View More
Technicals
- Beta 1.03
- 52 Week High $80
- 52 Week Low $53.95
- 50 Day Moving Average 75.5
- 200 Day Moving Average 67.62
View More
Dividends
- Dividend Date 2018-12-28
- ExDividend Date 2018-12-10
- Dividend Yield 0%
View More
Taro Pharmaceutical Industries Ltd (TARO) Dividend Calendar:
TARO's last dividend payment was made to shareholders on December 28, 2018.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Taro Pharmaceutical Industries Ltd (TARO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-01-27 | $N/A | $0.86 | $1.01 | -14.85% |
| 2020-09-30 | 2020-10-28 | $142.84 million | $1.18 | $0.77 | 53.25% |
| 2020-06-30 | 2020-07-29 | $N/A | -$11.37 | $1.16 | -1080.17% |
| 2020-03-31 | 2020-05-19 | $174.94 million | $1.42 | $1.53 | -7.19% |
| 2019-12-31 | 2020-02-03 | $147.68 million | $1.76 | $1.54 | 14.29% |
| 2019-09-30 | 2019-11-04 | $160.85 million | $1.46 | $1.72 | -15.12% |
| 2019-06-30 | 2019-08-08 | $161.3 million | $1.72 | $1.96 | -12.24% |
| 2019-03-31 | 2019-05-22 | $179.92 million | $1.52 | $2.26 | -32.74% |
| 2018-12-31 | 2019-02-07 | $176.38 million | $2.40 | $1.95 | 23.08% |
| 2018-09-30 | 2018-11-05 | $158.97 million | $1.60 | $1.96 | -18.37% |
| 2018-06-30 | 2018-08-09 | $154.62 million | $1.71 | $2.33 | -26.61% |
| 2018-03-31 | 2018-05-17 | $175.22 million | $2.17 | $1.51 | 43.71% |
| 2006-12-31 | 2007-03-20 | $252.27 million | -$0.27 | $0.07 | -485.71% |
| 2005-09-30 | 2005-11-17 | $72.54 million | $0.07 | $0.28 | -75% |
| 2005-06-30 | 2005-07-28 | $74.22 million | $0.22 | $0.28 | -21.43% |
| 2005-03-31 | 2005-04-26 | $78.54 million | $0.17 | $0.21 | -19.05% |
| 2004-12-31 | 2005-02-24 | $77.67 million | $0.16 | $0.12 | 33.33% |
| 2004-09-30 | 2004-10-28 | $73.28 million | $0.14 | $0.02 | 600% |
| 2004-06-30 | 2004-07-29 | $49.1 million | -$0.31 | $0.44 | -170.45% |
| 2004-03-31 | 2004-04-29 | $84.08 million | $0.37 | $0.53 | -30.19% |
| 2003-12-31 | 2004-02-17 | $88.62 million | $0.56 | $0.55 | 1.82% |
| 2003-09-30 | 2003-10-30 | $83.12 million | $0.53 | $0.52 | 1.92% |
| 2003-06-30 | 2003-07-24 | $74.75 million | $0.50 | $0.50 | 0% |
| 2003-03-31 | 2003-04-16 | $68.97 million | $0.47 | $0.45 | 4.44% |
| 2002-12-31 | 2003-02-20 | $61.98 million | $0.44 | $0.42 | 4.76% |
| 2002-09-30 | 2002-10-24 | $55.48 million | $0.39 | $0.38 | 2.63% |
| 2002-06-30 | 2002-07-23 | $49.58 million | $0.35 | $0.32 | 9.38% |
| 2002-03-31 | 2002-04-25 | $44.54 million | $0.34 | $0.32 | 6.25% |
| 2001-12-31 | 2002-02-21 | $43.46 million | $0.34 | $0.31 | 9.68% |
| 2001-09-30 | 2001-10-18 | $41.04 million | $0.29 | $0.26 | 11.54% |
| 2001-06-30 | 2001-07-19 | $36.36 million | $0.24 | $0.15 | 60% |
| 2001-03-31 | 2001-04-30 | $28.37 million | $0.11 | $0.10 | 10% |
| 2000-12-31 | 2001-02-22 | $29.95 million | $0.14 | $0.13 | 7.69% |
| 1997-12-31 | 1998-03-13 | $0.01 | $0.05 | -80% | |
| 1996-06-30 | 1996-07-25 | $0.03 | $0.03 | 0% | |
| 1996-03-31 | 1996-04-29 | $0.01 | $0.01 | 0% | |
| 1995-09-30 | 1995-10-26 | $0.06 | $0.04 | 50% | |
| 1994-12-31 | 1995-02-23 | $0.06 | $0.04 | 50% | |
| 1994-09-30 | 1994-11-01 | $0.04 | $0.06 | -33.33% | |
| 1994-06-30 | 1994-08-02 | $0.05 | $0.04 | 25% | |
| 1994-03-31 | 1994-05-11 | $0.03 | $0.01 | 200% |
Taro Pharmaceutical Industries Ltd (TARO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Taro Pharmaceutical Industries Ltd (TARO) Chart:
Taro Pharmaceutical Industries Ltd (TARO) News:
Below you will find a list of latest news for Taro Pharmaceutical Industries Ltd (TARO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Taro Pharmaceutical Industries Ltd (TARO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 22.5 | 0 | CALL | 0 | 0 | 189.61 | TRUE | 0 | 0 |
| 2024-05-17 | 25 | 0 | CALL | 0 | 0 | 158.32 | TRUE | 0 | 0 |
| 2024-05-17 | 30 | 0 | CALL | 0 | 0 | 112.03 | TRUE | 0 | 0 |
| 2024-05-17 | 35 | 0 | CALL | 0 | 0 | 71.58 | TRUE | 0 | 0 |
| 2024-05-17 | 40 | 0 | CALL | 0 | 0 | 48.91 | TRUE | 0 | 0 |
| 2024-05-17 | 45 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 50 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 55 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 60 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 22.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 25 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 30 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 35 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 40 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 45 | 0 | PUT | 0 | 0 | 42.22 | TRUE | 0 | 0 |
| 2024-05-17 | 50 | 0 | PUT | 0 | 0 | 71.66 | TRUE | 0 | 0 |
| 2024-05-17 | 55 | 0 | PUT | 0 | 0 | 96.34 | TRUE | 0 | 0 |
| 2024-05-17 | 60 | 0 | PUT | 0 | 0 | 117.2 | TRUE | 0 | 0 |
| 2024-06-21 | 22.5 | 0 | CALL | 0 | 0 | 93.97 | TRUE | 0 | 0 |
| 2024-06-21 | 25 | 0 | CALL | 0 | 0 | 165.2 | TRUE | 0 | 0 |
| 2024-06-21 | 30 | 0 | CALL | 0 | 0 | 123.45 | TRUE | 0 | 0 |
| 2024-06-21 | 35 | 0 | CALL | 0 | 0 | 87.24 | TRUE | 0 | 0 |
| 2024-06-21 | 40 | 0 | CALL | 0 | 0 | 36.29 | TRUE | 0 | 0 |
| 2024-06-21 | 45 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 50 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 55 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 60 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 22.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 25 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 30 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 35 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 40 | 0.3 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 45 | 0 | PUT | 0 | 0 | 24.91 | TRUE | 0 | 0 |
| 2024-06-21 | 50 | 0 | PUT | 0 | 0 | 43.67 | TRUE | 0 | 0 |
| 2024-06-21 | 55 | 0 | PUT | 0 | 0 | 59.08 | TRUE | 0 | 0 |
| 2024-06-21 | 60 | 0 | PUT | 0 | 0 | 72.17 | TRUE | 0 | 0 |
| 2024-07-19 | 20 | 0 | CALL | 0 | 0 | 175.21 | TRUE | 0 | 0 |
| 2024-07-19 | 22.5 | 0 | CALL | 0 | 0 | 152.88 | TRUE | 0 | 0 |
| 2024-07-19 | 25 | 0 | CALL | 0 | 0 | 133.13 | TRUE | 0 | 0 |
| 2024-07-19 | 30 | 0 | CALL | 0 | 0 | 99.06 | TRUE | 0 | 0 |
| 2024-07-19 | 35 | 0 | CALL | 0 | 0 | 25.04 | TRUE | 0 | 0 |
| 2024-07-19 | 40 | 3.8 | CALL | 0 | 8 | 8.02 | TRUE | 0 | 0 |
| 2024-07-19 | 45 | 0.2 | CALL | 0 | 129 | 9.62 | FALSE | 0 | 0 |
| 2024-07-19 | 50 | 0.45 | CALL | 0 | 24 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 20 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 22.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 25 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 30 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 35 | 0.1 | PUT | 0 | 9 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 40 | 0.25 | PUT | 3 | 66 | 15.02 | FALSE | 0.25 | 0 |
| 2024-07-19 | 45 | 0 | PUT | 0 | 0 | 19.32 | TRUE | 0 | 0 |
| 2024-07-19 | 50 | 0 | PUT | 0 | 0 | 35.55 | TRUE | 0 | 0 |
| 2024-10-18 | 22.5 | 0 | CALL | 0 | 0 | 111.42 | TRUE | 0 | 0 |
| 2024-10-18 | 25 | 0 | CALL | 0 | 0 | 96.82 | TRUE | 0 | 0 |
| 2024-10-18 | 30 | 0 | CALL | 0 | 0 | 16.21 | TRUE | 0 | 0 |
| 2024-10-18 | 35 | 0 | CALL | 0 | 0 | 19.86 | TRUE | 0 | 0 |
| 2024-10-18 | 40 | 0 | CALL | 0 | 0 | 17.82 | TRUE | 0 | 0 |
| 2024-10-18 | 45 | 0.2 | CALL | 0 | 16 | 5.05 | FALSE | 0 | 0 |
| 2024-10-18 | 50 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 55 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 60 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 22.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 25 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 30 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 35 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 40 | 0.3 | PUT | 0 | 1 | 10.28 | FALSE | 0 | 0 |
| 2024-10-18 | 45 | 0 | PUT | 0 | 0 | 10.95 | TRUE | 0 | 0 |
| 2024-10-18 | 50 | 0 | PUT | 0 | 0 | 49.09 | TRUE | 0 | 0 |
| 2024-10-18 | 55 | 0 | PUT | 0 | 0 | 60.42 | TRUE | 0 | 0 |
| 2024-10-18 | 60 | 0 | PUT | 0 | 0 | 69.96 | TRUE | 0 | 0 |
Latest TARO Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 100 | $35.2 |
| Jun 13, 2022 7:59 PM EST | 81 | $35.11 |
| Jun 13, 2022 7:59 PM EST | 19 | $35.11 |
| Jun 13, 2022 7:59 PM EST | 1 | $35.11 |
| Jun 13, 2022 7:59 PM EST | 5 | $35.08 |
Taro Pharmaceutical Industries Ltd (TARO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-19 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/906338/000156459020029846/0001564590-20-029846-index.htm |
| 2015-07-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/906338/000000000015037874/0000000000-15-037874-index.htm |
| 2015-08-24 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/906338/000000000015042769/0000000000-15-042769-index.htm |
| 2019-11-25 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/906338/000000000019015841/0000000000-19-015841-index.htm |
| 2020-01-21 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/906338/000000000020000502/0000000000-20-000502-index.htm |
| 2020-03-03 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/906338/000000000020001939/0000000000-20-001939-index.htm |
| 2020-05-07 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/906338/000000000020004002/0000000000-20-004002-index.htm |
| 2020-05-15 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/906338/000000000020004352/0000000000-20-004352-index.htm |
| 2020-02-20 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/906338/000094787120000134/0000947871-20-000134-index.htm |
| 2014-11-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752314004574/0001157523-14-004574-index.htm |
| 2014-12-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752314004876/0001157523-14-004876-index.htm |
| 2015-02-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315000421/0001157523-15-000421-index.htm |
| 2015-02-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315000502/0001157523-15-000502-index.htm |
| 2015-05-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315001853/0001157523-15-001853-index.htm |
| 2015-05-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315001903/0001157523-15-001903-index.htm |
| 2015-07-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315002648/0001157523-15-002648-index.htm |
| 2015-08-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315002827/0001157523-15-002827-index.htm |
| 2015-08-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315002847/0001157523-15-002847-index.htm |
| 2015-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315003168/0001157523-15-003168-index.htm |
| 2015-10-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315003456/0001157523-15-003456-index.htm |
| 2015-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315003668/0001157523-15-003668-index.htm |
| 2015-11-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315003864/0001157523-15-003864-index.htm |
| 2015-11-24 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315003920/0001157523-15-003920-index.htm |
| 2015-12-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752315004117/0001157523-15-004117-index.htm |
| 2016-02-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316004396/0001157523-16-004396-index.htm |
| 2016-02-03 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316004423/0001157523-16-004423-index.htm |
| 2016-02-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316004544/0001157523-16-004544-index.htm |
| 2016-03-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316004934/0001157523-16-004934-index.htm |
| 2016-05-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316005352/0001157523-16-005352-index.htm |
| 2016-05-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316005693/0001157523-16-005693-index.htm |
| 2016-05-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316005759/0001157523-16-005759-index.htm |
| 2016-06-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316005850/0001157523-16-005850-index.htm |
| 2016-06-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316005928/0001157523-16-005928-index.htm |
| 2016-07-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316006047/0001157523-16-006047-index.htm |
| 2016-08-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316006500/0001157523-16-006500-index.htm |
| 2016-08-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316006570/0001157523-16-006570-index.htm |
| 2016-09-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316006685/0001157523-16-006685-index.htm |
| 2016-10-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316006815/0001157523-16-006815-index.htm |
| 2016-10-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316007128/0001157523-16-007128-index.htm |
| 2016-11-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316007315/0001157523-16-007315-index.htm |
| 2016-11-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316007450/0001157523-16-007450-index.htm |
| 2016-11-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316007457/0001157523-16-007457-index.htm |
| 2016-12-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316007505/0001157523-16-007505-index.htm |
| 2016-12-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316007592/0001157523-16-007592-index.htm |
| 2016-12-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752316007629/0001157523-16-007629-index.htm |
| 2017-01-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317000022/0001157523-17-000022-index.htm |
| 2017-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317000255/0001157523-17-000255-index.htm |
| 2017-02-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317000422/0001157523-17-000422-index.htm |
| 2017-02-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317000483/0001157523-17-000483-index.htm |
| 2017-05-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317001574/0001157523-17-001574-index.htm |
| 2017-05-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317001634/0001157523-17-001634-index.htm |
| 2017-06-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317001826/0001157523-17-001826-index.htm |
| 2017-08-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317002324/0001157523-17-002324-index.htm |
| 2017-09-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317002436/0001157523-17-002436-index.htm |
| 2017-09-01 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317002437/0001157523-17-002437-index.htm |
| 2017-10-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317002877/0001157523-17-002877-index.htm |
| 2017-11-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317003044/0001157523-17-003044-index.htm |
| 2017-11-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752317003142/0001157523-17-003142-index.htm |
| 2018-01-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318000012/0001157523-18-000012-index.htm |
| 2018-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318000174/0001157523-18-000174-index.htm |
| 2018-02-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318000244/0001157523-18-000244-index.htm |
| 2018-05-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318001106/0001157523-18-001106-index.htm |
| 2018-05-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318001145/0001157523-18-001145-index.htm |
| 2018-06-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318001330/0001157523-18-001330-index.htm |
| 2018-08-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318001680/0001157523-18-001680-index.htm |
| 2018-08-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318001792/0001157523-18-001792-index.htm |
| 2018-09-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318001995/0001157523-18-001995-index.htm |
| 2018-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318002180/0001157523-18-002180-index.htm |
| 2018-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318002315/0001157523-18-002315-index.htm |
| 2018-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318002340/0001157523-18-002340-index.htm |
| 2018-12-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318002546/0001157523-18-002546-index.htm |
| 2018-12-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752318002647/0001157523-18-002647-index.htm |
| 2019-01-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752319000074/0001157523-19-000074-index.htm |
| 2019-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752319000199/0001157523-19-000199-index.htm |
| 2019-02-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752319000247/0001157523-19-000247-index.htm |
| 2019-05-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752319001247/0001157523-19-001247-index.htm |
| 2019-05-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752319001287/0001157523-19-001287-index.htm |
| 2019-06-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752319001430/0001157523-19-001430-index.htm |
| 2019-08-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752319001785/0001157523-19-001785-index.htm |
| 2019-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752319002183/0001157523-19-002183-index.htm |
| 2019-12-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000115752319002332/0001157523-19-002332-index.htm |
| 2015-07-01 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/906338/000119312515241661/0001193125-15-241661-index.htm |
| 2015-07-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/906338/000119312515266184/0001193125-15-266184-index.htm |
| 2019-11-15 | SC TO-I | Tender offer statement by Issuer | https://www.sec.gov/Archives/edgar/data/906338/000119312519293464/0001193125-19-293464-index.htm |
| 2019-12-03 | SC TO-I/A | Tender offer statement by Issuer | https://www.sec.gov/Archives/edgar/data/906338/000119312519305368/0001193125-19-305368-index.htm |
| 2019-12-03 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/906338/000119312519305377/0001193125-19-305377-index.htm |
| 2019-12-17 | SC TO-I/A | Tender offer statement by Issuer | https://www.sec.gov/Archives/edgar/data/906338/000119312519316301/0001193125-19-316301-index.htm |
| 2019-12-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000119312519316304/0001193125-19-316304-index.htm |
| 2019-12-20 | SC TO-I/A | Tender offer statement by Issuer | https://www.sec.gov/Archives/edgar/data/906338/000119312519319505/0001193125-19-319505-index.htm |
| 2016-06-09 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/906338/000156459016020459/0001564590-16-020459-index.htm |
| 2017-06-21 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/906338/000156459017012807/0001564590-17-012807-index.htm |
| 2018-06-21 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/906338/000156459018015952/0001564590-18-015952-index.htm |
| 2019-06-20 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/906338/000156459019022978/0001564590-19-022978-index.htm |
| 2019-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459019040590/0001564590-19-040590-index.htm |
| 2019-11-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459019043595/0001564590-19-043595-index.htm |
| 2019-12-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459019046671/0001564590-19-046671-index.htm |
| 2019-12-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459019046673/0001564590-19-046673-index.htm |
| 2019-12-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459019047125/0001564590-19-047125-index.htm |
| 2020-01-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459020000779/0001564590-20-000779-index.htm |
| 2020-02-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459020003089/0001564590-20-003089-index.htm |
| 2020-02-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459020003756/0001564590-20-003756-index.htm |
| 2020-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459020005681/0001564590-20-005681-index.htm |
| 2020-04-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459020015435/0001564590-20-015435-index.htm |
| 2020-04-10 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/906338/000156459020016218/0001564590-20-016218-index.htm |
| 2020-05-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/906338/000156459020025671/0001564590-20-025671-index.htm |
| 2020-05-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459020026236/0001564590-20-026236-index.htm |
| 2020-06-19 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/906338/000156459020029846/0001564590-20-029846-index.htm |
| 2020-07-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459020033276/0001564590-20-033276-index.htm |
| 2020-07-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459020034379/0001564590-20-034379-index.htm |
| 2020-10-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459020048410/0001564590-20-048410-index.htm |
| 2020-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/906338/000156459020050361/0001564590-20-050361-index.htm |